An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

NCT06443944 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Non-Muscle Invasive Bladder Cancer
Urothelial Carcinoma
Urologic Cancer
Bladder Cancer

Interventions

DRUG: Cretostimogene Grenadenorepvec
OTHER: n-dodecyl-B-D-maltoside

Sponsor

CG Oncology, Inc.